SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Lidak Pharm. [LDAKA]

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: luis a. garcia who wrote (359)8/14/1997 7:22:00 PM
From: henry jakala   of 1115
 
in any case it appears our ship has come in to some extent - finally Lidakol seems to have justified its potential - seems the placebo was inactive this time and Lidak is quite confident of its results

so how long before Lidak starts distribution to the medical community and revenues start coming in ?

are there any other hurdles it will now face ?

as far as i recall, Lidakol performed better than the current antivirals in European trials - no mention of how it actually stacks up against drugs currently on the market ?

also the mention of aborting the onset seems to be something that would be highly marketable - any idea how the medical community will respond to the arrival of Lidakol ?

one last point - will Lidakol be prescription only or over the counter ? we did have that discussion on its non-mutagenic properties but was anyone able to determine the final status ?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext